^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | GLR2007 (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1 Drug Candidate GLR2007 Developed by Gan & Lee has been Granted Fast Track Designation by the U.S. FDA
Published date:
01/29/2021
Excerpt:
Gan & Lee Pharmaceuticals...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for GLR2007, for the treatment of patients with glioblastoma.
